SCPEP1 (Serine Carboxypeptidase 1), also known as prolylcarboxypeptidase or PRCP, is a lysosomal enzyme belonging to the serine carboxypeptidase family. It catalyzes the cleavage of C-terminal amino acids linked to proline, playing roles in regulating peptide hormones like angiotensin III and prekallikrein. SCPEP1 is implicated in various physiological processes, including blood pressure regulation, inflammation, and energy metabolism.
Antibodies targeting SCPEP1 are valuable tools for studying its expression, localization, and function in both normal and pathological contexts. They are widely used in techniques such as Western blotting, immunohistochemistry, and immunofluorescence to investigate SCPEP1's involvement in diseases like hypertension, obesity, and cancer. For instance, elevated SCPEP1 levels have been observed in certain tumors, suggesting potential roles in tumor progression or metabolic reprogramming.
Commercial SCPEP1 antibodies are typically raised in hosts like rabbits or mice, with validation data confirming specificity through knockdown/knockout controls. Researchers utilize these antibodies to explore therapeutic targeting opportunities, particularly in metabolic disorders or angiogenesis-related conditions. However, variability in antibody performance across experimental setups necessitates careful validation for reproducibility. Current studies continue to clarify SCPEP1's mechanistic pathways, aided by reliable antibody reagents.